Americas Cancer Biological Therapy Market Overview
Americas Cancer Biologic Therapy Market Size was valued at USD 90.20 Billion in 2023. The Americas Cancer Biologic Therapy industry is projected to grow from USD 98.40 Billion in 2024 to USD 104.70 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.40% during the forecast period (2024 - 2032).
Cancer is characterized by uncontrolled growth of cells. It is one of the deadliest disease in the world and the second cause for death. Cancer can be defined as an abnormal cell growth with the potential to spread to other part of the body. There are over 100 types of cancer which has affected human.
Biological therapy uses living organism for the treatment of a disease. These therapies are consist of monoclonal antibodies, vaccines, interferons and many more. Many therapies are available for the treatment of cancer but none of the treatment assure the cure of cancer. The major factors responsible for the growth of the cancer biological therapies are increasing number of patient and limited option of therapy. Bedside this patent expiry of cancer drug increase the demand of the biological treatment. High cost for development of new drug and many adverse effect of the therapy can hamper the market growth.
Study objectives of Americas Cancer Biological Therapy Market
- To provide the Detail Overview of parent market.
- To provide In-depth market segmentation and sub segmentations.
- To provide insights about factors affecting the market growth
- To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide Competitive landscape and key players in the market
- To provide historical and forecast revenue of the market segments and sub-segments with respect to three main geographies and their countries- US, Canada and Rest of America.
- To provide country level analysis of the market with respect to the current market size and future prospective
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Americas Cancer Biological Therapy market.
Intended Audience Americas Cancer Biological Therapy Market
- Cancer Biological Therapy devices manufacturers
- Cancer Biological Therapy devices suppliers
- Biotechnology Companies
- Research and Development (R&D) Companies
- Government Research Laboratories
- Medical Research Institutes
Key Players for Cancer Biological Therapy Market
Hoffmann-La Roche AG, GSK, Merck & Co., Novartis International AG, Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Amgen Inc., Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation and others.
Americas Cancer Biological Therapy market has been segmented on the basis of:
- By types which comprises of monoclonal antibodies (Naked monoclonal antibodies, Conjugated monoclonal antibodies, other), interferons, interleukins, cancer growth inhibitors (Tyrosine kinase inhibitors, mTOR inhibitors and Proteasome inhibitors), gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others.
- On the basis of end user, market is segmented into hospitals & clinics, cancer research centers, laboratories and others.
- And on the basis of Region market is segmented as US, Canada and Rest of America.
Americas Cancer Biological Therapy Market Regional Analysis
On regional Basis, America’s biologic cancer therapy market is segmented as US, Canada and Rest of America. The market is dominated by U.S. and Canada due to technological advances and funding available for the development of new therapeutics and treatment. Moreover, increasing number of cancer patient is also driving the market for cancer biologic therapy in this region.
The report for Americas Cancer Biological Therapy market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Report Attribute/Metric |
Details |
Market Size |
USD 104.70 Billion by 2032 |
CAGR |
  8.40% (2024-2032) |
Base Year |
  2023 |
Forecast Period |
  2024-2032 |
Historical Data |
  2022 |
Forecast Units |
 Value (USD Billion) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth    Factors, and Trends |
Segments Covered |
Types, end user, Region |
Geographies Covered |
US, Canada, and Rest of America |
  Key Vendors |
Hoffmann-La Roche AG, GSK, Merck & Co., Novartis International AG, Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Amgen Inc., Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation and others |
Key Market Opportunities |
Technological advances and funding available for the development of new therapeutics and treatment |
Key Market Drivers |
Increasing number of patients, limited option of therapy, patent expiry of cancer drug |
Americas Cancer Biologic Therapy Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report